XML 55 R39.htm IDEA: XBRL DOCUMENT v3.20.2
Revenue - Narrative (Details) - USD ($)
3 Months Ended 12 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Jun. 30, 2020
Revenue from Contract with Customer [Abstract]      
Advance Medicare payments to provide relief from economic impacts of COVID-19     $ 29,700,000
Revenue, practical expedient, remaining performance obligation, description In accordance with ASU 2014-09, the Company has elected not to disclose the aggregate amount of the transaction price allocated to remaining performance obligations for its contracts that are one year or less, as the revenue is expected to be recognized within the next year. Furthermore, the Company has elected not to disclose the aggregate amount of the transaction price allocated to remaining performance obligations for its agreements wherein the Company’s right to payment is in an amount that directly corresponds with the value of Company’s performance to date. However, the Company periodically enters into arrangements with customers to provide diagnostic testing and/or pharmaceutical and clinical services that may have terms longer than one year and include multiple performance obligations.    
Revenue, practical expedient, remaining performance obligation true    
Revenue, remaining performance obligation $ 2,800,000    
Accrued refund liability $ 2,200,000    
Revenue practical expedient, incremental cost of obtaining contract true    
Capitalized costs incurred to obtain or fulfill contract $ 0    
Revenues | Medicare      
Concentration Risk [Line Items]      
Concentration risk (percent) 16.00% 14.00%